{
    "clinical_study": {
        "@rank": "73876", 
        "arm_group": {
            "arm_group_label": "Treatment (lenalidomide, combination chemotherapy)", 
            "arm_group_type": "Experimental", 
            "description": "LENALIDOMIDE PRIMING: Patients receive lenalidomide PO for 5 or 7 days.\nRE-INDUCTION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5. Patients failing to achieve blast count < 5% at 21 days may receive a second course of induction therapy. Patients achieving complete remission proceed to lenalidomide priming.\nLENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and then proceed to consolidation therapy.\nCONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and the best dose of lenalidomide when given\n      together with combination chemotherapy in treating patients with relapsed or refractory\n      acute myeloid leukemia. Lenalidomide may stop the growth of acute myeloid leukemia by\n      blocking blood flow to the cancer. Drugs used in chemotherapy, such as mitoxantrone\n      hydrochloride, etoposide, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Giving\n      lenalidomide and combination chemotherapy may be an effective treatment for acute myeloid\n      leukemia."
        }, 
        "brief_title": "Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", 
        "condition": [
            "Adult Acute Megakaryoblastic Leukemia (M7)", 
            "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", 
            "Adult Acute Monoblastic Leukemia (M5a)", 
            "Adult Acute Monocytic Leukemia (M5b)", 
            "Adult Acute Myeloblastic Leukemia With Maturation (M2)", 
            "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", 
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Adult Acute Myelomonocytic Leukemia (M4)", 
            "Adult Erythroleukemia (M6a)", 
            "Adult Pure Erythroid Leukemia (M6b)", 
            "Recurrent Adult Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Erythroblastic, Acute", 
                "Leukemia, Megakaryoblastic, Acute", 
                "Leukemia, Monocytic, Acute", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelomonocytic, Acute", 
                "Leukemia, Myelomonocytic, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the maximum tolerated dose (MTD) of lenalidomide when used in combination\n      with mitoxantrone hydrochloride, etoposide, and cytarabine (MEC) in patients with relapsed\n      or refractory acute myeloid leukemia (AML).\n\n      II. To determine the dose-limiting toxicities (DLTs) of this combination in this patient\n      population.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine whether the combination of lenalidomide priming prior to re-induction\n      chemotherapy with MEC has clinical activity in patients with relapsed or refractory AML.\n\n      OUTLINE: This is a dose-escalation study of lenalidomide.\n\n      LENALIDOMIDE PRIMING: Patients receive lenalidomide orally (PO) for 5 or 7 days.\n\n      RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide intravenously (IV) over 1 hour,\n      cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days\n      1-5. Patients failing to achieve blast count < 5% at 21 days may receive a second course of\n      induction therapy. Patients achieving complete remission proceed to lenalidomide priming.\n\n      LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and\n      then proceed to consolidation therapy.\n\n      CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3\n      hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats\n      every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable\n      toxicity.\n\n      After completion of study treatment, patients are followed up for 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients eligible include those with diagnosis of AML other than acute promyelocytic\n             leukemia by World Health Organization (WHO) criteria with relapsed disease after\n             induction therapy or refractory to induction chemotherapy, as determined by\n             morphology on bone marrow biopsy; also eligible are patients unwilling to receive\n             standard induction chemotherapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n          -  Serum creatinine =< 1.5 mg/dL; if serum creatinine > 1.5 mg/dL, then the estimated\n             glomerular filtrate rate (GFR) must be > 60ml/min/1.73m^2 as calculated by the\n             Modification of Diet in Renal Disease equation\n\n          -  Serum bilirubin =< 1.5 x upper limit of normal (ULN) unless elevation is considered\n             to be secondary to Gilbert's syndrome, hemolysis, or hepatic infiltration by AML\n\n          -  Aspartate transaminase (AST)/alanine transaminase (ALT) =< 2.5 x ULN\n\n          -  Alkaline phosphatase =< 2.5 x ULN\n\n          -  All study participants must be registered into the mandatory Revlimid assistance\n             (RevAssist) program, and be willing and able to comply with the requirements of\n             RevAssist\n\n          -  Females of childbearing potential (FCBP) must have a negative serum or urine\n             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again\n             within 24 hours prior to prescribing lenalidomide for cycle 1 (prescriptions must be\n             filled within 7 days as required by RevAssist) and must either commit to continued\n             abstinence from heterosexual intercourse or begin TWO acceptable methods of birth\n             control, one highly effective method and one additional effective method AT THE SAME\n             TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to\n             ongoing pregnancy testing; men must agree to use a latex condom during sexual contact\n             with a FCBP even if they have had a successful vasectomy\n\n        Exclusion Criteria:\n\n          -  Patient must not undergo concomitant radiotherapy, chemotherapy or immunotherapy;\n             patient must not be in concurrent study with other investigational agents\n\n          -  Patients who have received prior lenalidomide therapy are not eligible for this\n             study; further there should be at least a 14-day window from the patient's last prior\n             therapy before initiation of treatment on clinical trial\n\n          -  Have other severe concurrent disease or serious organ dysfunction involving the\n             heart, kidney, liver or other organ system that may place the patient at undue risk\n             to undergo treatment\n\n          -  Have significant, uncontrolled active infection\n\n          -  Pregnant or nursing patients will be excluded from the study\n\n          -  Known human immunodeficiency virus (HIV) infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01904643", 
            "org_study_id": "HEMAML0024", 
            "secondary_id": [
                "NCI-2013-01349", 
                "27313", 
                "P30CA124435"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (lenalidomide, combination chemotherapy)", 
                "description": "Given PO", 
                "intervention_name": "lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CC-5013", 
                    "IMiD-1", 
                    "Revlimid"
                ]
            }, 
            {
                "arm_group_label": "Treatment (lenalidomide, combination chemotherapy)", 
                "description": "Given IV", 
                "intervention_name": "mitoxantrone hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CL 232315", 
                    "DHAD", 
                    "DHAQ", 
                    "Novantrone"
                ]
            }, 
            {
                "arm_group_label": "Treatment (lenalidomide, combination chemotherapy)", 
                "description": "Given IV", 
                "intervention_name": "etoposide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "EPEG", 
                    "VP-16", 
                    "VP-16-213"
                ]
            }, 
            {
                "arm_group_label": "Treatment (lenalidomide, combination chemotherapy)", 
                "description": "Given IV", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARA-C", 
                    "arabinofuranosylcytosine", 
                    "arabinosylcytosine", 
                    "Cytosar-U", 
                    "cytosine arabinoside"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Thalidomide", 
                "Etoposide phosphate", 
                "Lenalidomide", 
                "Etoposide", 
                "Mitoxantrone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "contact": {
                "email": "jtaw@stanford.edu", 
                "last_name": "Jack Taw", 
                "phone": "650-723-1269"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Hospitals and Clinics"
            }, 
            "investigator": {
                "last_name": "Bruno C. de Medeiros", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Lenalidomide Therapy Prior to Re-induction Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine (MEC) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)", 
        "overall_official": {
            "affiliation": "Stanford University Hospitals and Clinics", 
            "last_name": "Bruno de Medeiros", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hematologic and non-hematologic toxicities will be tabulated.", 
            "measure": "MTD of lenalidomide when used in combination with MEC determined by DLT using the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), version 4.0", 
            "safety_issue": "Yes", 
            "time_frame": "42 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01904643"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportions of these patients in each response category will be tabulated; the combined proportion in categories CR, CRi, PR, and SD will be computed along with an exact 95% confidence interval.", 
                "measure": "Response rate (complete remission [CR], CR with incomplete blood count recovery [CRi], partial remission [PR] or stable disease [SD]) using LeukemiaNet guidelines", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Summarized using a Kaplan-Meier plot.", 
                "measure": "Response duration", 
                "safety_issue": "No", 
                "time_frame": "From start of induction, assessed up to 6 months"
            }, 
            {
                "description": "Summarized using a Kaplan-Meier plot.", 
                "measure": "Early mortality", 
                "safety_issue": "No", 
                "time_frame": "From start of induction, assessed up to 6 months"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}